ERBB2 and neoplasm: Abnormal activation of HER2 can activate downstream pathways such as PI3K/Akt and MEK/MAPK through the formation of homologous or heterologous dimers, which leads to abnormal proliferation of tumor cells and the production of osimertinib resistance.